RBC Capital Sticks to Their Buy Rating for R1 RCM (RCM)

In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on R1 RCM (RCM – Research Report), with a price target of $19.00. The company’s shares closed yesterday at $12.84.

Dodge covers the Healthcare sector, focusing on stocks such as R1 RCM, Sotera Health, and Evolent Health. According to TipRanks, Dodge has an average return of -7.1% and a 38.21% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for R1 RCM with a $16.64 average price target, a 29.60% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $16.00 price target.

RCM market cap is currently $5.4B and has a P/E ratio of -160.70.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

R1 RCM (RCM) Company Description:

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.